Study of Fluoxetine in Patients With Depersonalization Disorder
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00004446|
Recruitment Status : Completed
First Posted : October 19, 1999
Last Update Posted : June 24, 2005
The purpose of this study is to:
1) Determine the effects of fluoxetine in the treatment of depersonalization disorder, 2) Assess the durability of treatment response in these patients, 3) Assess the improvement in psychiatric disability in these patients, and 4) Assess the effects of comorbid Axis I disorders (depression, social phobia, panic/anxiety, obsessive-compulsive disorder) and Axis II personality disorders on treatment outcome in these patients.
|Condition or disease||Intervention/treatment|
|Depersonalization Disorder||Drug: fluoxetine|
In this trial, participants will be randomly assigned to receive either fluoxetine or placebo. Treatment will consists of two phases (acute treatment and maintenance). In the acute treatment phase, participants will receive fluoxetine or placebo daily for 12 weeks. Participants will be followed every 2 weeks. In the Maintenance phase, participants showing significant improvement after 12 weeks may continue treatment for an additional 6 months. In this phase, participants are followed every 4 weeks.
Participants who do not improve during the acute treatment phase may receive open fluoxetine, or another appropriate medication, for 3 months.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||80 participants|
|Study Start Date :||April 1998|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00004446
|United States, New York|
|Mount Sinai Medical Center, NY|
|New York, New York, United States, 10029|
|Study Chair:||Daphne Simeon||Icahn School of Medicine at Mount Sinai|